Precision Medicine in Oncology: Individualized Treatment Approaches Through Patient Profiling

CDK 4/6 Inhibitors

• 0:27 - Switching to a different CDK 4/6 inhibitor after progression on a previous one
• 0:55 - Using ESR1 mutation status to guide treatment decisions with CDK 4/6 inhibitors
• 1:01 - Combining CDK 4/6 inhibitors with different endocrine therapies
• 1:38 - Exploring the benefit of CDK 4/6 inhibitors in endocrine-sensitive populations

ESR1 Mutation

• 2:02 - Detecting ESR1 mutations before radiological progression to improve treatment outcomes
• 2:18 - Switching endocrine therapy upon detection of ESR1 mutation without radiological progression

PI3K Inhibitors

• 3:41 - Combining PI3K inhibitors with fulvestrant in PI3K mutant populations
• 4:29 - Using PI3K inhibitors in the first-line setting for PI3K mutant populations

AKT Inhibitors

• 5:07 - Using AKT inhibitors in the second-line setting for PI3K mutant populations
• 5:15 - Combining AKT inhibitors with fulvestrant in PI3K mutant populations

Oral SERDs

• 9:18 - Combining oral SERDs with CDK 4/6 inhibitors

Discussion

• 22:30 - Testing oral SERDs in combination with other biological agents
• 27:03 - Testing for PI3K mutations in the second-line setting
• 27:10 - Using liquid biopsy for ESR1 mutation detection
• 28:25 - Using oral SERDs as a replacement for fulvestrant in the metastatic setting
• 29:11 - Using oral SERDs in the adjuvant setting